Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. - Test2 - elhamkhani - TriplyDB

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

http://www.wikidata.org/entity/Q33387673

about

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.

P2860

Q33733758-56265EAB-4AE6-461F-B21E-CBC211E69D89 Q35222202-EA7EC332-FB40-4ABF-8534-8DD655FA2EBA

P2860

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

http://www.wikidata.org/entity/Q33387673

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@ast

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@en

type

label

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@ast

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@en

prefLabel

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@ast

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@en

P1433

Q33387673-79CEC3F4-ED1B-407C-AF61-0628C663613A

P1476

Q33387673-5F49AF96-3CB4-46CC-B2BC-2E8359942CB9

P2093

Q33387673-45039D0D-CE46-4FCF-91EB-C077B4551FC7

Q33387673-68711259-2CB5-4635-8294-39291E16D5D5

Q33387673-7E183C47-018F-4128-82C5-27D31CE90AA3

Q33387673-8FD3821E-6447-4D68-8F83-92CAF98F45C2

Q33387673-A59FAF6F-B0C6-41C4-889B-4EB841196029

Q33387673-B10A9D0A-49E3-44CC-818D-04C05C54A771

Q33387673-C35B3E79-C75F-4BD6-B635-51624AA29CDD

Q33387673-CDB5BD80-14AA-495D-B0A3-746679DCA929

Q33387673-D9D088DA-5855-4CFF-9170-3A6180940B0E

P2860

Q33387673-244ADE8B-9A9C-4397-A179-2860E606B412

Q33387673-408CDE7B-714E-4EC3-ACAF-3511D7B08292

Q33387673-4F4A1FE6-911D-43E2-86A7-71AFE1F41A9F

Q33387673-6566A358-E541-4033-BD20-D17F3E09FFA3

Q33387673-6CFA94DA-734E-4D7A-8B29-0FFABD4659CD

Q33387673-891948D8-61A6-4A1D-B422-968AD4FBF971

Q33387673-982A9195-FDDE-4B5F-BBB1-497DEFE081D1

Q33387673-98526500-AA96-408E-97BE-0092081DF1F4

Q33387673-987F9D5F-C36B-4CBB-9BEE-56BD5B1E5FA7

Q33387673-A44DB951-F991-4DEB-9358-9BDAD97CAD9B

P304

Q33387673-28D34960-94C4-4E04-BB54-A2E6CEADA2F4

P31

Q33387673-29278D57-4741-499D-A76E-3E0EF65D70BE

P407

Q33387673-7FC975EB-C41A-488A-9571-897F5CDFA6CF

P433

Q33387673-96CAAAAE-AE72-406A-9D26-D8D6473D9D96

P478

Q33387673-984D84EF-CBF1-4EA2-8F46-44FBDEC60CB1

P577

Q33387673-91B733F8-75D1-42B8-B3A7-FA18FCB0B27F

P698

Q33387673-87E07AD9-A726-495E-A656-62B5A0DB71FB

P932

Q33387673-67B793EC-8AFC-405D-8929-872DC0C3AF56

P1433

Anticancer Research

P1476

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

@en

P2093

Elizabeth Dugan

http://www.w3.org/2001/XMLSchema#string

Gerald C Blobe

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Jon P Gockerman

http://www.w3.org/2001/XMLSchema#string

Kellen L Meadows

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Nishan H Fernando

http://www.w3.org/2001/XMLSchema#string

Roxanne Truax

http://www.w3.org/2001/XMLSchema#string

William P Petros

http://www.w3.org/2001/XMLSchema#string

P2860

DNA T OPOISOMERASES : Structure, Function, and Mechanism

Mammalian deoxyribonucleoside kinases

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.

Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.

Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents.

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

P304

5149-5153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20044630

http://www.w3.org/2001/XMLSchema#string

P932

4103184

http://www.w3.org/2001/XMLSchema#string